Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Juvenile Idiopathic Arthritis (Phase 3, China cohort of global study)
CTR20191178Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in Polyarticular rheumatoid factor-positive juvenile idiopathic arthritis, juvenile idiopathic arthritis (JIA), juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), sponsored by Eli Lilly and Company. Started Oct 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
Polyarticular rheumatoid factor-positive juvenile idiopathic arthritisjuvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on CTR20191178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191178.